8-K: Amicus Therapeutics Announces Preliminary 2024 Revenue and 2025 Strategic Outlook

Amicus Therapeutics reports strong 2024 revenue growth of 32% and provides a positive strategic outlook for 2025, driven by Galafold and Pombiliti + Opfolda.

Summary

• Amicus Therapeutics announced preliminary 2024 total revenue of $528.5 million, a 32% increase year-over-year.
• The company anticipates total revenue growth of 17-24% in 2025 on a constant currency basis.
• Galafold net product sales reached $458.2 million in 2024, an 18% increase year-over-year, with approximately 2,730 patients on Galafold as of the end of 2024.
• Pombiliti + Opfolda net product sales were $70.3 million in 2024, with approximately 220 patients treated or scheduled with commercial product as of the end of 2024.
• Amicus expects Pombiliti + Opfolda revenue to grow by 65-85% in 2025 on a constant currency basis.
• The company anticipates achieving positive GAAP Net Income during the second half of 2025.
• Amicus reached a settlement with Teva, preventing Teva from commercializing generic migalastat in the U.S. until January 2037.
• Amicus anticipates surpassing $1 billion in total sales in 2028.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, successful product launches, and anticipated profitability. The settlement with Teva and long-term growth projections further contribute to a favorable sentiment.

Positives

• Strong revenue growth of 32% in 2024.
• Successful launch of Pombiliti + Opfolda with $70.3 million in sales.
• Growing patient demand for Galafold, with 2,730 patients on treatment.
• Positive outlook for 2025 with projected revenue growth for both Galafold and Pombiliti + Opfolda.
• Anticipated positive GAAP Net Income in the second half of 2025.
• Settlement with Teva provides long-term patent protection for Galafold in the U.S. until 2037.
• Expected to surpass $1 billion in total sales by 2028.
• Multiple Pombiliti + Opfolda pricing and reimbursement agreements recently achieved in Italy, Sweden, Switzerland, and Czech Republic.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including regulatory approvals, pricing and reimbursement negotiations, commercialization success, competition, manufacturing and supply, and the need for additional funding.
• Exchange rate fluctuations could impact reported revenues, with a +/1% change potentially affecting total reported revenues by ~$3.6M in 2025.
• A variance between Year-End 2024 and Full-Year 2024 USD exchange rates of ~4% would translate into a negative impact of ~$15M on Total Revenue in 2025 if rates were to remain at Year-End 2024 level.

Future Outlook

Amicus Therapeutics anticipates continued revenue growth driven by Galafold and Pombiliti + Opfolda, with a focus on expanding market reach and label indications. The company expects to achieve positive GAAP Net Income during the second half of 2025 and surpass $1 billion in total sales by 2028.

Management Comments

• Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., said, 'For Amicus, 2024 was a remarkable year in which we set out high expectations and met or exceeded each of them.'
• Mr. Campbell also stated that the company delivered significant revenue growth of 32% in addition to Full Year non-GAAP profitability.
• He further noted that the company grew its core Galafold business and delivered a strong first full year of launch for Pombiliti + Opfolda while securing regulatory and reimbursement milestones that provide the foundation for sustained double-digit growth in 2025 and beyond.
• Mr. Campbell believes that the combination of two approved medicines in growing markets, a strong intellectual property position, accelerating profitability, and a unique and leverageable global rare disease organization will enable the company to deliver sustainable revenue growth and expand its portfolio over time.
• He stated that Amicus has the capabilities and infrastructure to achieve its vision to become one of the leading rare disease companies bringing transformative therapies to patients and creating significant value for shareholders.

Industry Context

Amicus Therapeutics operates in the rare disease market, focusing on Fabry and Pompe diseases. The company's performance is influenced by factors such as regulatory approvals, reimbursement agreements, and competition from other therapies. The global Fabry market is estimated at ~$2.1B in 2024 and is projected to grow to ~$3B+ by the end of the decade. The global Pompe market is estimated at ~$1.5B in 2024 and is projected to grow to ~$2B+ by 2029.

Comparison to Industry Standards

• Amicus's Galafold competes with enzyme replacement therapies (ERTs) in the Fabry disease market, such as Fabrazyme (Sanofi) and Replagal (Takeda).
• Galafold's oral administration and unique mechanism of action offer a differentiated approach compared to traditional ERTs.
• Pombiliti + Opfolda competes with Lumizyme (Sanofi) in the Pompe disease market.
• Pombiliti + Opfolda's two-component therapy and inclusion of ERT-experienced patients in its Phase 3 study provide a unique profile compared to existing therapies.
• The company's projected revenue growth rates for Galafold and Pombiliti + Opfolda are competitive within the rare disease market.

Stakeholder Impact

• Shareholders can expect continued revenue growth and potential profitability.
• Patients will benefit from increased access to Galafold and Pombiliti + Opfolda.
• Employees can anticipate a stable and growing company with opportunities for career development.
• The company's commitment to ESG principles will positively impact the environment and society.

Next Steps

• Deliver total revenue growth of 17-24% at CER in 2025.
• Achieve Galafold revenue growth of 10-15% at CER in 2025.
• Achieve Pombiliti + Opfolda revenue growth of 65-85% at CER in 2025.
• Advance ongoing studies to broaden labels and strengthen scientific leadership in Fabry and Pompe diseases.
• Deliver positive GAAP Net Income during H2 2025.
• Launch Pombiliti + Opfolda in up to 10 new countries in 2025.
• Continue to build the body of evidence to support planned label expansion for Pombiliti + Opfolda.

Key Dates